Церетон®

General characteristics. Structure:

1 ampoule (4 ml) contains in quality of active agent of sincaline of an alfostserat polyhydrate (in terms of anhydrous sincaline альфосцерат) - 1000 mg,
excipients: water for injections - to 4 ml.

Description: transparent colourless liquid.

Pharmacological properties:

Pharmacodynamics. Nootropic means. The central holinostimulyator as a part of which 40,5% of metabolic protected sincaline contain. Metabolic protection promotes release of sincaline in a brain. Provides synthesis of acetylcholine and phosphatidylsincaline in neyronalny membranes, improves a blood stream and strengthens metabolic processes in the central nervous system, activates a reticular formation. Increases the linear speed of a blood-groove on the party of traumatic damage of a brain, contributes to normalization of spatio-temporal characteristics of spontaneous bioelectric activity of a brain, regress of focal neurologic symptoms and recovery of consciousness; exerts positive impact on cognitive and behavioural reactions of patients with vascular diseases of a brain (distsirkulyatorny encephalopathy and the residual phenomena of disturbance of cerebral circulation). Has preventive and corrective effect on pathogenetic factors of an involutional psychoorganic syndrome, changes phospholipidic structure of membranes of neurons and reduces cholinergic activity. Stimulates dozozavisimy allocation of acetylcholine in physiological conditions; participating in phosphatidylsincaline synthesis (membrane phospholipid), improves synoptic transfer, plasticity of neyronalny membranes, function of receptors. Does not exert impact on a reproductive cycle and does not possess teratogenic, mutagen action.

Pharmacokinetics. Easily gets through a blood-brain barrier, 85% are excreted by lungs in the form of carbon dioxide, other quantity (15%) is removed by kidneys and through intestines.

Indications to use:

- The acute and recovery periods heavy cherepno - a brain injury and an ischemic stroke, the recovery period of a hemorrhagic stroke, proceeding with focal polusharny symptomatology or symptoms of defeat of a brainstem;
- a psychoorganic syndrome against the background of degenerative and involutional changes of a brain;
- cognitive frustration (disturbances of cogitative function, memory, confusion, consciousnesses, a disorientation, decrease in motivation, initiative and ability to concentration of attention), including at dementia and encephalopathy;
- senile pseudo-melancholy.

Route of administration and doses:

At acute states enter intravenously (slowly) or deeply intramusculary 1000 mg (1 ampoule) a day within 10-15 days.

Features of use:

Церетон® does not exert impact on the speed of psychomotor reactions.

Side effects:

From the alimentary system: lock, diarrhea, dryness of a mucous membrane of an oral cavity, pharyngitis.
From a nervous system: headache, drowsiness, sleeplessness, aggression, alarm, nervousness, ischemia of a brain, spasm, dizziness.
From integuments: rash, urticaria.
Others: pain in an injection site, increase of an urination.
Allergic reactions.
Emergence of nausea is possible (mainly as a result of dopaminergic activation), in this case reduce a drug dose.

Interaction with other medicines:

Significant interaction with other drugs is not revealed.

Contraindications:

Hypersensitivity to drug or its components
hemorrhagic stroke (acute stage);
children's age up to 18 years;
pregnancy;
breastfeeding period

Use at pregnancy and during breastfeeding

Use of the drug Tsereton® during pregnancy and during breastfeeding is contraindicated. For the period of treatment by the drug Tsereton® it is necessary to stop feeding by a breast.

Overdose:

Nausea can be noted. Treatment: symptomatic therapy.

Storage conditions:

To store in the place protected from light at a temperature not above 25 °C. To store in the place, unavailable to children. Period of validity: 4 years. Not to use after a period of validity.

Issue conditions:

According to the recipe

Packaging:

Solution for intravenous and intramuscular administration of 250 mg/ml.
On 4 ml in ampoules of colourless neutral glass type I with a color ring of a break or with a color point and a notch. One, two or three color rings and/or a two-dimensional barcode, and/or the alphanumeric coding or without additional color rings, a two-dimensional barcode, the alphanumeric coding in addition apply on ampoules. On 3 or 5 ampoules in a blister strip packaging.
On 1 or 2 blister strip packagings together with the application instruction in a pack from a cardboard.